PHASIQ’s Board of Directors and our Executive Leadership, CEO Francis Glorie and Founder and CSO Shuichi Takayama, have named Jim Vincke PHASIQ’s Chief Financial Officer. Vincke comes to PHASIQ with extensive experience in financial leadership in entrepreneurial companies. He has led public offerings as well as mergers and acquisitions. According to Francis Glorie, PHASIQ’s CEO, […]
PHASIQ CEO Francis Glorie attended the NSF 2015 SBIR/STTR Awardee Conference June 1-June 4, 2015 in Atlanta, Georgia. This annual conference brings together companies, investors, and potential partners. Attending companies have won Small Business Innovation Research (SBIR) grants or Small Business Technology Transfer (STTR) grants. PHASIQ participated in the technology showcase at the event.
Lisa Eiden joined the PHASIQ team in May 2015 as a Research Technician. Lisa has an undergraduate and a Master’s degree in Biomedical engineering from Karlsruhe Institute of Technology. Prior to joining PHASIQ, Lisa worked at Novartis in Basel, Switzerland, Böhringer Ingelheim in Ingelheim, Germany, Bosch Packaging Technology Pharma in Crailsheim, Germany, and Bioingenium in Barcelona, […]
In April, 2015 GenomeWeb profiled PHASIQ and our recent grant award. Immunoassay developer PhasiQ this week received a two-year grant from the National Science Foundation to develop and commercialize an ELISA-based multiplex protein biomarker test for identifying patients with deep vein thrombosis (DVT). Read the full article on the GenomeWeb site.
At our recent Board of Directors meeting, Francis Glorie, MBA, was officially named Chief Executive Officer of PHASIQ. Glorie comes to PHASIQ after successful tenures in business development and leadership at biotech firms such as Tangent Medical Technologies, Inc. and Accuri Cytometers, Inc. Glorie is also seasoned entrepreneurial mentor, currently he is an Entrepreneur in Residence at TechTown […]